 The former President of Israel, Reuven Rivlin, with the first vaccinator in Phase B of the IIBR-100 vaccine of the Israel Institute for Biological Research, at the Barzilai Medical Center. | |
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Viral vector |
| Clinical data | |
| Other names | Brilife |
| Routes of administration | Intramuscular |
| ATC code |
|
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
 COVID-19 portal |
BriLife, also known as IIBR-100, is a replication-competent recombinant VSV viral vectored COVID-19 vaccine candidate.[1][2][3][4] It was developed by the Israel Institute for Biological Research (IIBR).[1][5][6] The IIBR partnered with the US-based NRx Pharmaceuticals to complete clinical trials and commercialize the vaccine.[7][8] A study conducted in hamsters suggested that one dose of the vaccine was safe and effective at protecting against COVID-19.[9][3]
YouTube Encyclopedic
-
1/1Views:3 223
-
Video Testimony - Bancassurance Financial Advisor, BRI Life 2018
Transcription
References
- ^ a b Karpiński TM, Ożarowski M, Seremak-Mrozikiewicz A, Wolski H, Wlodkowic D (1 January 2021). "The 2020 race towards SARS-CoV-2 specific vaccines". Theranostics. 11 (4): 1690–1702. doi:10.7150/thno.53691. PMC 7778607. PMID 33408775.
- ^ Bezbaruah R, Borah P, Kakoti BB, Al-Shar'I NA, Chandrasekaran B, Jaradat DM, et al. (2021). "Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19". Frontiers in Molecular Biosciences. 8: 635337. doi:10.3389/fmolb.2021.635337. PMC 8082173. PMID 33937326.
- ^ a b Pushparajah D, Jimenez S, Wong S, Alattas H, Nafissi N, Slavcev RA (March 2021). "Advances in gene-based vaccine platforms to address the COVID-19 pandemic". Advanced Drug Delivery Reviews. 170: 113–141. doi:10.1016/j.addr.2021.01.003. PMC 7789827. PMID 33422546.
- ^ Venkadapathi J, Govindarajan VK, Sekaran S, Venkatapathy S (9 June 2021). "A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on Clinical Trials". Frontiers in Molecular Biosciences. 8: 637378. doi:10.3389/fmolb.2021.637378. PMC 8219860. PMID 34179072.
- ^ Clinical trial number NCT04608305 for "Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults" at ClinicalTrials.gov
- ^ Scarabel L, Guardascione M, Dal Bo M, Toffoli G (March 2021). "Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19". International Journal of Infectious Diseases. 104: 441–451. doi:10.1016/j.ijid.2021.01.035. PMC 7816887. PMID 33476760.
- ^ Rabinovitch A, Williams D (12 July 2021). Grebler D (ed.). "Israel partners with NRx Pharmaceuticals to commercialize COVID vaccine". Reuters. Retrieved 10 November 2021.
- ^ "Israeli-produced vaccine shipped to Georgia for Phase II trial". i24 News. 15 August 2021. Retrieved 10 November 2021.
- ^ Yahalom-Ronen Y, Tamir H, Melamed S, Politi B, Shifman O, Achdout H, et al. (December 2020). "A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge". Nature Communications. 11 (1): 6402. doi:10.1038/s41467-020-20228-7. PMC 7745033. PMID 33328475.
External links
- IIBR-100 entry at Stanford Medicine
- Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine
Scholia has a profile for BriLife (Q100694835).
Wikimedia Commons has media related to BriLife.
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
 | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 19 September 2023, at 20:13